Sean Marett, BioNTech CBO and CCO
April 8, 2022 01:00 PM EDTUpdated 01:12 PM
R&D
Manufacturing

Rid­ing on coat­tails of Comir­naty suc­cess, BioN­Tech wins mR­NA man­u­fac­tur­ing con­tract with Ger­man gov­ern­ment

Paul Schloesser

Associate Editor

Ger­man biotech and wild­ly suc­cess­ful Pfiz­er part­ner, BioN­Tech, has notched its next con­tract on home turf, cour­tesy of the Ger­man gov­ern­ment.

The biotech, who part­nered …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times